Molecular characterization of HIV type 1 in Brazzaville, Republic of Congo, and first data on resistance to antiretroviral drugs

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1798-1802

  Pircher, Mathilde ^a,b   Diafouka, Merlin ^b   Papuchon, Jennifer ^a   Recordon Pinson, Patricia ^a   Mahambou, Dominique Nsonde ^b   Akolbout, Maryse ^b   Simon, Bernard ^c   Fleury, Hervé ^a  

^a University Victor Segalen   (France)

^b Centre Hospitalier et Universitaire de Brazzaville   (Congo)

^c National à la Croix Rouge Française   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONGO; DRUG RESISTANCE; DRUG RESISTANCE MUTATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; VIRUS IDENTIFICATION; VIRUS ISOLATION;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CLUSTER ANALYSIS; CONGO; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84870052573     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0083     Document Type: Article

References (17)

1. Tebit DM and Arts EJ: Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011;11:45-56.
2. http://hiv.lanl.gov/
3. Molez JF: The historical question of acquired immunodeficiency syndrome in the 1960s in the Congo River basin area in relation to cryptococcal meningitis. Am J Trop Med Hyg 1998;58:273-276.
4. Niama FR, Toure-Kane C, Vidal N, et al.: HIV-1 subtypes and recombinants in the Republic of Congo. Infect Genet Evol 2006;6:337-343.
5. Bikandou B, N'Doundou-N'Kodia MY, et al.: Genetic subtyping of gag and env regions of HIV type 1 isolates in Republic of Congo. AIDS Res Hum Retroviruses, 2004;20:1005-1009.
6. Taniguchi Y, Takehisa J, Bikandou B, et al.: Genetic subtypes of HIV type 1 based on the vpu/env sequences in the Republic of Congo. AIDS Res Hum Retroviruses 2001;18:79-83.
7. Bikandou B, Takehisa J, Mboudjeka I, et al.: Genetic subtypes of HIV type 1 in Republic of Congo. AIDS Res Hum Ret-roviruses 2000;16:613-619.
8. Mboudjeka I, Bikandou B, Zekeng L, et al.: Genetic diversity of HIV-1 group M from Cameroon and Republic of Congo. Arch Virol 1999;144:2291-2311.
9. Candotti, D, Tareau C, Barin F, et al.: Genetic subtyping and V3 serotyping of HIV type 1 isolates in Congo. AIDS Res Hum Retroviruses 1999;15:309-314.
10. Deshpande A, Karki S, Recordon-Pinson P, and Fleury HJ: Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses 2011;27:1345-1347.
11. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance:2009 update. PLoS One 2009;4:e4724.
12. Carr JK, Wolfe ND, Torimiro JN, et al.: HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: Evolutionary relics? Retrovirology 2010;7:39.
13. Djoko C, Rimoin A, Vidal N, et al.: High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo. AIDS Res Hum Retroviruses 2011;27:323-329.
14. Aghokeng AF, Vergne L, Mpoudi-Ngole E, et al.: Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 2009;14:401-411.
15. Mintsa-Ndong A, Caron M, Plantier JC, et al.: High HIV type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in Northeast Gabon, Central Africa. AIDS Res Hum Retroviruses 2009;25:411-418.
16. Péré H, Charpentier C, Mbelesso P, et al.: Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic. AIDS Res Hum Retroviruses 2011;27:1-9.
17. De Luca A, Cingolani A, Di Giambenedetto S, et al.: Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003;187:1934-1943.